Detection of ERG gene rearrangements and PTEN deletions in unsuspected prostate cancer of the transition zone

Cancer Biology and Therapy

Volumn 11, Issue 6, 2011, Pages 562-566

  Liu, Shuhong ^a   Yoshimoto, Maisa ^b   Trpkov, Kiril ^a,c   Duan, Qiuli ^c   Firszt, Matthew ^d   Corcos, Jacques ^e   Squire, Jeremy A ^b   Bismar, Tarek A ^a,c,f  

^a UNIVERSITY OF CALGARY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c TOM BAKER CANCER CENTRE   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

ERG rearrangements; FISH; PTEN genomic deletion; Transition zone

Indexed keywords

BIOLOGICAL MARKER; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRANSCRIPTION FACTOR ERG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE REARRANGEMENT; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROSTATE CANCER; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; SEQUENCE DELETION; TRANS-ACTIVATORS; TRANSURETHRAL RESECTION OF PROSTATE; TUMOR MARKERS, BIOLOGICAL;

EID: 79952770944     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.6.14376     Document Type: Article

References (40)

1. Hermans KG, Boormans JL, Gasi D, van Leenders GJ, Jenster G, Verhagen PC, et al. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer. Clin Cancer Res 2009; 15:6398-403.
2. Darnel AD, Lafargue CJ, Vollmer RT, Corcos J, Bismar TA. TMPRSS2-ERG fusion is frequently observed in gleason pattern 3 prostate cancer in a canadian cohort. Cancer Biol Ther 2009; 88:125-30.
3. Saramaki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL, Visakorpi T. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 2008; 14:3395-400.
4. Hu Y, Dobi A, Sreenath T, Cook C, Tadase AY, Ravindranath L, et al. Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin Cancer Res 2008; 14:4719-25.
5. FitzGerald LM, Agalliu I, Johnson K, Miller MA, Kwon EM, Hurtado-Coll A, et al. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer 2008; 8:230.
6. Tu JJ, Rohan S, Kao J, Kitabayashi N, Mathew S, Chen YT. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol 2007; 20:921-8. (Pubitemid 47267823)
7. Rajput AB, Miller MA, De Luca A, Boyd N, Leung S, Hurtado-Coll A, et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 2007; 60:1238-43. (Pubitemid 350084545)
8. Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 2007; 31:882-8. (Pubitemid 47165141)
9. Nami RK, Sugar L, Wang Z, Yang W, Kitching R, Klotz LH, et al. Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther 2007; 6:40-5. (Pubitemid 46294173)
10. Nam RK, Sugar L, Yang W, Srivastava S, Klotz LH, Yang LY, et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 2007; 97:1690-5. (Pubitemid 350249347)
11. Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007; 26:4596-9. (Pubitemid 47037039)
12. Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2007; 26:4596-9.
13. Wang J, Cai Y, Ren C, Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006; 66:8347-51. (Pubitemid 44449142)
14. Mehra R, Tomlins SA, Shen R, Nadeem O, Wang L, Wei JT, et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007; 20:538-44. (Pubitemid 46631996)
15. Bismar TA, Yoshimoto M, Vollmer RT, Duan Q, Firszt M, Corcos J, et al. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer. BJU Int 2010; 107:477-485.
16. Han B, Mehra R, Lonigro RJ, Wang L, Suleman K, Menon A, et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol 2009; 22:1083-93.
17. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009; 69:2912-8.
18. Yoshimoto M, Joshua AM, Cunha IW, Coudry RA, Fonseca FP, Ludkovski O, et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol 2008; 21:1451-60.
19. Reid AH, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, et al. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 102:678-84.
20. Gopalan A, Leversha MA, Satagopan JM, Zhou Q, Al-Ahmadie HA, Fine SW, et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 2009; 69:1400-6.
21. Squire JA. TMPRSS2-ERG and PTEN loss in prostate cancer. Nat Genet 2009; 41:509-10.
22. King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, et al. Cooperativity of TMPRSS2- ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 2009; 41:524-6.
23. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 2009; 41:619-24.
24. Sobin LHWC. TNM Classification of Malignant Tumours. In: Cancer IUA, Ed. TNM Classification of Malignant Tumours. New York, NY: Wiley-Liss 2002; 184-7.
25. McDowell PR, Fox WM, Epstein JI. Is submission of remaining tissue necessary when incidental carcinoma of the prostate is found on transurethral resection? Hum Pathol 1994; 25:493-7.
26. Trpkov K, Thompson J, Kulaga A, Yilmaz A. How much tissue sampling is required when unsuspected minimal prostate carcinoma is identified on transurethral resection? Arch Pathol Lab Med 2008; 132:1313-6.
27. Cantrell BB, DeKlerk DP, Eggleston JC, Boitnott JK, Walsh PC. Pathological factors that influence prognosis in stage A prostatic cancer: the influence of extent versus grade. J Urol 1981; 125:516-20. (Pubitemid 11116651)
28. Blute ML, Zincke H, Farrow GM. Long-term followup of young patients with stage A adenocarcinoma of the prostate. J Urol 1986; 136:840-3. (Pubitemid 16026229)
29. Epstein JI, Paull G, Eggleston JC, Walsh PC. Prognosis of untreated stage A1 prostatic carcinoma: a study of 94 cases with extended followup. J Urol 1986; 136:837-9. (Pubitemid 16026228)
30. Lowe BA, Listrom MB. Incidental carcinoma of the prostate: an analysis of the predictors of progression. J Urol 1988; 140:1340-4. (Pubitemid 19003166)
31. Thompson IM, Zeidman EJ. Extended follow-up of stage A1 carcinoma of prostate. Urology 1989; 33:455-8. (Pubitemid 19159593)
32. Roy CR, 2nd, Horne D, Raife M, Pienkos E. Incidental carcinoma of prostate, long-term follow-up. Urology 1990; 36:210-3. (Pubitemid 20304415)
33. van Andel G, Vleeming R, Kurth K, de Reijke TM. Incidental carcinoma of the prostate. Semin Surg Oncol 1995; 11:36-45.
34. Cheng L, Neumann RM, Blute ML, Zincke H, Bostwick DG. Long-term follow-up of untreated stage T1a prostate cancer. J Natl Cancer Inst 1998; 90:1105-7. (Pubitemid 28350280)
35. Lowe BA. Management of stage T1a prostate cancer. Semin Urol Oncol 1996; 14:178-82. (Pubitemid 26269469)
36. Guo CC, Zuo G, Cao D, Troncoso P, Czerniak BA. Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion. Mod Pathol 2009; 22:866-71.
37. Bismar TA, Trpkov K. TMPRSS2-ERG gene fusion in transition zone prostate cancer. Mod Pathol 23:1040-1.
38. Falzarano SM, Navas M, Simmerman K, Klein EA, Rubin MA, Zhou M, et al. ERG rearrangement is present in a subset of transition zone prostatic tumors. Mod Pathol 23:1499-506.
39. Darnel AD, Lafargue CJ, Vollmer RT, Corcos J, Bismar TA. TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort. Cancer Biol Ther 2009; 8:125-30.
40. Yoshimoto M, Cunha IW, Coudry RA, Fonseca FP, Torres CH, Soares FA, et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 2007; 97:678-85. (Pubitemid 47339893)